CAH Stock Recent News

Dividend Aristocrats are outperforming the S&P 500 in 2025, demonstrating resilience, with NOBL up 1.78% YTD versus SPY's 4.9% decline. Top performers include Consolidated Edison (+22.98%), Brown & Brown (+20.65%), and AbbVie (+16.61%), showcasing strong double-digit gains. 29 out of 69 Dividend Aristocrats have announced dividend increases in 2025, with an average growth rate of 4.15%.

Here is how Cardinal Health (CAH) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here we discuss five non-tech stocks that have provided double-digit returns year to date, defying the negative trends of U.S. stock markets. These are TPR, WEC, CNP, CME and CEH.

Cardinal Health's recent acquisitions and GMPD recovery look promising. However, the loss of the Optum Rx contract and margin pressure are likely to hurt short-term prospects.

Cardinal Health (CAH) closed at $133.98 in the latest trading session, marking a +0.93% move from the prior day.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Cardinal Health (CAH) concluded the recent trading session at $132.75, signifying a -0.35% move from its prior day's close.

DUBLIN, Ohio , March 25, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2025 on May 1, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m.